SBIR-STTR Award

Universal Antivenom
Award last edited on: 8/10/2016

Sponsored Program
SBIR
Awarding Agency
DOD : DARPA
Total Award Amount
$1,100,474
Award Phase
2
Solicitation Topic Code
SB142-004
Principal Investigator
Che-Ming J Hu

Company Information

Arytha Biosciences LLC

10225 Barnes Canyon Road, Suite A209
San Diego, CA 92121
   (858) 509-4778
   info@arythabio.com
   www.arythabio.com
Location: Single
Congr. District: 52
County: San Diego

Phase I

Contract Number: N/A
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2012
Phase I Amount
$100,000
A broadly applicable antivenom treatment is critical to protecting warfighters from animal envenoming in austere environments. The objective of this research project is to apply a cell membrane cloaked nanoparticle platform to neutralize the hemolytic component found in many animal venoms. In the Phase I technical report, we demonstrate that biomimetic nanoparticles consisting of polymeric cores enclosed in red blood cell membrane bilayers can spontaneously absorb and neutralize a number of protein toxins that are known to attack and disrupt cellular membranes. The nanoparticle platform can be safely administered as it is comprised entirely of biocompatible and biodegradable materials. In the direct-to-Phase II proposal, we aim to obtain the data necessary for nanosponges regulatory approval as an antivenom platform. The formulations efficacy against several well-known animal venoms, its safety, and its pharmacokinetics and biodistributions will be assessed.

Phase II

Contract Number: W91NF-15-C-0010
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2014
Phase II Amount
$1,000,474
A broadly applicable antivenom treatment is critical to protecting warfighters from animal envenoming in austere environments. The objective of this research project is to apply a cell membrane cloaked nanoparticle platform to neutralize the hemolytic component found in many animal venoms. In the Phase I technical report, we demonstrate that biomimetic nanoparticles consisting of polymeric cores enclosed in red blood cell membrane bilayers can spontaneously absorb and neutralize a number of protein toxins that are known to attack and disrupt cellular membranes. The nanoparticle platform can be safely administered as it is comprised entirely of biocompatible and biodegradable materials. In the direct-to-Phase II proposal, we aim to obtain the data necessary for nanosponges regulatory approval as an antivenom platform. The formulations efficacy against several well-known animal venoms, its safety, and its pharmacokinetics and biodistributions will be assessed.